In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ARCA biopharma, Nuvelo in reverse merger

Executive Summary

Heart disease company ARCA biopharma is going public by merging with Nuvelo (cancer and cardiovascular diseases) in a stock swap. ARCA shareholders will own about 67% of the newly combined company, which will focus on cardiovascular therapeutics. The combination will take ARCA's name.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies

UsernamePublicRestriction

Register